May 21, 2021 -- Japan recently granted special approval for emergency use of AstraZeneca's COVID-19 vaccine, Vaxzevria, in patients ages 18 years and older.
The Japanese Ministry of Health, Labour and Welfare granted the approval based on positive efficacy and safety data from the Oxford University-led clinical trial program in the U.K., Brazil, and South Africa, and a phase II trial in Japan. Production of the vaccine in Japan is underway, and the first doses are expected to be available in the coming weeks.
Japan's Pharmaceuticals and Medical Devices Agency recommends that the use of Vaxzevria should be limited to adults and administered intramuscularly as two 0.5-mL doses given four to 12 weeks apart, with an interval greater than eight weeks being preferable to maximize its efficacy.
Copyright © 2021 scienceboard.net